Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | ATTO | DNA |
|---|---|---|
| Price | $15.72 | $11.29 |
| Change today | ▼ 4.26% | ▼ 1.57% |
| Market cap | $717.64M | $760.27M |
| Return, 3 months | – | +16.0% |
| Return, year to date | – | +35.9% |
| Return, 1 year | – | -29.8% |
| P/E (TTM) | -10.2 | -2.3 |
| P/B | -4.9 | 1.8 |
| P/E percentile vs own 5y | 90th | 30th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -48.5% |
| Net profit growth (YoY) | -43.3% | +22.5% |
| Gross margin | – | 68.0% |
| Operating margin | -4,232.9% | -228.6% |
| Net margin | -3,910.0% | -219.6% |
| Return on equity | – | -56.3% |
| Analyst target vs. price | +152.9% | -38.0% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 35 | 57 |
| 30-day volatility | 76.9% | 125.7% |
| Max drawdown, 1 year | -35.7% | -66.0% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Sell |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
